Key Business Insights for PM Developers: Navigating Reimbursement Hurdles and Demonstrating Clinical Utility to Payers
  For developers of Precision Medicine (PM) diagnostics and therapeutics, securing actionable precision medicine market Business Insights means recognizing that reimbursement is often a greater commercial hurdle than regulatory approval. The high cost of PM products—whether a complex NGS panel or a targeted therapy—requires developers to move beyond simply demonstrating...
0 Reacties 0 aandelen 2K Views 0 voorbeeld